{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:48Z","timestamp":1793747088425,"version":"4.6.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10620-024-08720-2","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T12:54:38Z","timestamp":1731070478000},"page":"4437-4445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"69","author":[{"given":"Jo\u00eblle","family":"St-Pierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Fear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Pannain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"8720_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"GG Kaplan","year":"2021","unstructured":"Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:56\u201366. https:\/\/doi.org\/10.1038\/s41575-020-00360-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8720_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NH Phelps","year":"2024","unstructured":"Phelps NH, Singleton RK, Zhou B, Heap RA, Mishra A, Bennett JE et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet 2024;403:1027\u20131050. https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2.","journal-title":"The Lancet"},{"key":"8720_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","volume":"14","author":"S Singh","year":"2017","unstructured":"Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nature Reviews Gastroenterology and Hepatology 2017;14:110\u2013121. https:\/\/doi.org\/10.1038\/nrgastro.2016.181.","journal-title":"Nature Reviews Gastroenterology and Hepatology"},{"key":"8720_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/crocol\/otad007","volume":"5","author":"A Elangovan","year":"2023","unstructured":"Elangovan A, Shah R, Ali SMJ, Katz J, Cooper GS. High burden of obesity and low rates of weight loss pharmacotherapy in inflammatory bowel disease: 10-year trend. Crohn\u2019s and Colitis 360 2023;5:1\u20138. https:\/\/doi.org\/10.1093\/crocol\/otad007.","journal-title":"Crohn\u2019s and Colitis 360"},{"key":"8720_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41575-022-00658-y","volume":"19","author":"TE Adolph","year":"2022","unstructured":"Adolph TE, Meyer M, Schw\u00e4rzler J, Mayr L, Grabherr F, Tilg H. The metabolic nature of inflammatory bowel diseases. Nature Reviews Gastroenterology and Hepatology 2022;19:753\u2013767. https:\/\/doi.org\/10.1038\/s41575-022-00658-y.","journal-title":"Nature Reviews Gastroenterology and Hepatology"},{"key":"8720_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3748\/wjg.v29.i12.1779","volume":"29","author":"JH Kim","year":"2023","unstructured":"Kim JH, Yoo JH, Oh CM. Obesity and novel management of inflammatory bowel disease. World Journal of Gastroenterology 2023;29:1779\u20131794. https:\/\/doi.org\/10.3748\/wjg.v29.i12.1779.","journal-title":"World Journal of Gastroenterology"},{"key":"8720_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/ajg.2012.453","volume":"108","author":"SSM Chan","year":"2013","unstructured":"Chan SSM, Luben R, Olsen A, Tjonneland A, Kaaks R, Teucher B et al. Body mass index and the risk for Crohn\u2019s disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). The American Journal of Gastroenterology 2013;108:575\u2013582. https:\/\/doi.org\/10.1038\/ajg.2012.453.","journal-title":"The American Journal of Gastroenterology"},{"key":"8720_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3390\/biom9120780","volume":"9","author":"J Bilski","year":"2019","unstructured":"Bilski J, Mazur-Bialy A, Wojcik D, Surmiak M, Magierowski M, Sliwowski Z et al. Role of obesity, mesenteric adipose tissue, and adipokines in inflammatory bowel diseases. Biomolecules 2019;9:780. https:\/\/doi.org\/10.3390\/biom9120780.","journal-title":"Biomolecules"},{"key":"8720_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cgh.2018.07.004","volume":"17","author":"NH Nguyen","year":"2019","unstructured":"Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. Obesity is independently associated with higher annual burden and costs of hospitalization in patients with inflammatory bowel diseases. Clinical Gastroenterology and Hepatology 2019;17:709-718.e7. https:\/\/doi.org\/10.1016\/j.cgh.2018.07.004.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"8720_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/ueg2.12349","volume":"10","author":"Y Yin","year":"2022","unstructured":"Yin Y, Xie Y, Ge W, Li Y. Creeping fat formation and interaction with intestinal disease in Crohn\u2019s disease. United European Gastroenterology Journal 2022;10:1077\u20131084. https:\/\/doi.org\/10.1002\/ueg2.12349.","journal-title":"United European Gastroenterology Journal"},{"key":"8720_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/MIB.0000000000000283","volume":"21","author":"H Khalili","year":"2015","unstructured":"Khalili H, Ananthakrishnan AN, Konijeti GG, Higuchi LM, Fuchs CS, Richter JM et al. Measures of obesity and risk of Crohn\u2019s disease and ulcerative colitis. Inflammatory Bowel Diseases 2015;21:361\u2013368. https:\/\/doi.org\/10.1097\/MIB.0000000000000283.","journal-title":"Inflammatory Bowel Diseases"},{"key":"8720_CR12","doi-asserted-by":"publisher","unstructured":"Jensen CB., \u00c4ngquist LH., Mendall MA., S\u00f8rensen TIA., Baker JL., Jess T. Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study. The American Journal of Gastroenterology 2018;113:694\u2013701. https:\/\/doi.org\/10.1038\/s41395-018-0031-x.","DOI":"10.1038\/s41395-018-0031-x"},{"key":"8720_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics 2009;42:377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"Journal of Biomedical Informatics"},{"key":"8720_CR14","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L et al. The REDCap consortium: building an international community of software platform partners. Journal of Biomedical Informatics 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","journal-title":"Journal of Biomedical Informatics"},{"key":"8720_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/nejmoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/nejmoa2032183.","journal-title":"New England Journal of Medicine"},{"key":"8720_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/nejmoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine 2022;387:205\u2013216. https:\/\/doi.org\/10.1056\/nejmoa2206038.","journal-title":"New England Journal of Medicine"},{"key":"8720_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae090","author":"A Desai","year":"2024","unstructured":"Desai A, Khataniar H, Hashash JG. Effectiveness and safety of semaglutide for weight loss in patients with inflammatory bowel disease and obesity. Inflammatory Bowel Diseases. 2024. https:\/\/doi.org\/10.1093\/ibd\/izae090.","journal-title":"Inflammatory Bowel Diseases"},{"key":"8720_CR18","doi-asserted-by":"publisher","first-page":"100979","DOI":"10.1016\/j.eclinm.2021.100979","volume":"37","author":"M Villumsen","year":"2021","unstructured":"Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine 2021;37:100979. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100979.","journal-title":"EClinicalMedicine"},{"key":"8720_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.935823","volume":"13","author":"X Gao","year":"2022","unstructured":"Gao X, Hua X, Wang X, Xu W, Zhang Y, Shi C et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology 2022;13:1\u201314. https:\/\/doi.org\/10.3389\/fphar.2022.935823.","journal-title":"Frontiers in Pharmacology"},{"key":"8720_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj\u00e6r MS, Krarup N et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. The Lancet Gastroenterology and Hepatology 2023;8:511\u2013522. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7.","journal-title":"The Lancet Gastroenterology and Hepatology"},{"key":"8720_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1053\/j.gastro.2013.08.036","volume":"145","author":"MS Siddiqui","year":"2013","unstructured":"Siddiqui MS, Sterling RK, Luketic VA, Puri P, Stravitz RT, Bouneva I et al. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013;145:1271\u20131273. https:\/\/doi.org\/10.1053\/j.gastro.2013.08.036.","journal-title":"Gastroenterology"},{"key":"8720_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","volume":"47","author":"B Calvarysky","year":"2024","unstructured":"Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review. Drug Safety 2024;47:439\u2013451. https:\/\/doi.org\/10.1007\/s40264-023-01392-3.","journal-title":"Drug Safety"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08720-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:12:21Z","timestamp":1732709541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08720-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["8720"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08720-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4740528\/v1","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SP: SP has served as a consultant for Noro Nordisk and Lilly, she receives research support from Amgen and Novo Nordisk, she is in the Speaker\u2019s Bureau for Novo Nordisk and Lilly. JSP, JK, NKC, EF: No conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was reviewed and approved by the Institutional Review Board (IRB, Ethics Board) at the University of Chicago. Each subject provided informed consent (IRB protocol 15573A).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}